We've been invited to share our clinical findings on NTI164 at the International International Rett Syndrome Foundation Foundation Scientific Meeting, 9–11 June in Boston. Our Principal Investigator, Professor Carolyn Ellaway, will present both a poster and an oral presentation detailing outcomes from

We’ve appointed Dr. Bonni Goldstein as our Chief Medical Advisor USA. Dr. Goldstein brings more than 25 years of clinical experience, including 17 years focused exclusively on cannabinoid-based therapeutics. She is internationally recognised for her work treating thousands of

Watch the latest Stockhead interview with Professor Michael Fahey, a leading Paediatric Neurologist and Clinical Geneticist at Monash Medical Centre, as he shares his experience using our #NTI164 drug in the treatment of #ASD and Rett syndrome. He discusses how NTI164 is

We've published our Phase I/II Rett syndrome clinical trial results in the peer-reviewed scientific journal, Journal of Paediatrics and Child Health. The study, titled “Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An

In a recent Stockhead interview, our Chief Medical Advisor (USA), Dr. Bonni Goldstein, discusses NTI164 - our cannabinoid-based therapy currently in development for autism spectrum disorder, Rett Syndrome, and PANS/PANDAS. Dr. Goldstein shares her journey from paediatric

🗞️ Neurotech’s Rett Syndrome trial results published in scientific journal | AusBiotech. biotechdispatch.com.au/news/neurotech… $NTI #Biotech #Neurotech

We've received a powerful caregiver statement highlighting the impact of #NTI164 in a child with moderate Autism Spectrum Disorder (#ASD): “As a parent of a child diagnosed with moderate Autism Spectrum Disorder, I have observed significant and encouraging changes since

We’re pleased to share that our CEO, Dr Anthony Filippis, will be speaking at the 2025 Bioshares Biotech Summit, held 7–8 August in Hobart. Anthony will take part in Session 3: Deal Making – The Real Story, a panel discussion exploring the complexities and practical realities of

Our Quarterly Activities Report for the period ending 30 June 2025 has been released. View the full $NTI report: api.investi.com.au/api/announceme… #Biotech #Neurotech #ASX #ASXNews #NTI164 #NTI

“NTI164 demonstrated safety and improved some clinical and functional outcomes in RTT [Rett],” Researchers wrote. “These improvements justify ongoing research into #NTI164, which may be a potential adjunct therapy in RTT.” Media coverage by Bionews, Inc. rettsyndromenews.com/news/cannabis-…

"Neurotech’s June quarter was marked by important clinical progress, growing international recognition, and further regulatory engagement for its lead investigational therapy #NTI164, a proprietary #CBDA-rich #cannabinoid formulation being developed for #paediatric neurological

We’ve been featured in Australian in an article exploring new treatments for Rett syndrome, a rare and complex paediatric neurological condition. Read more: theaustralian.com.au/business/stock… $NTI #Neurotech #ASX #NTI #RettSyndrome #NTI164 #PaediatricNeurology #CannabinoidTherapy

Our Managing Director & CEO, Anthony Filippis joined today’s “Deal Making: The Real Story” panel at the 2025 Bioshares Biotech Summit, alongside fellow biotech leaders sharing real-world lessons on navigating transactions, partnerships, and growth. Thanks to Bioshares for

The U.S. is considering moving #marijuana from a Schedule I to a Schedule III substance, a change that could make life a lot easier for companies working with #cannabinoid-based medicines. While #NTI164 is already developed and trialled within Australia’s regulatory framework,

"In my clinical practice, I’ve seen how full-spectrum cannabinoid therapies can profoundly improve the lives of children with autism, Rett syndrome, and PANS." – Dr. Bonni Goldstein MD, Neurotech Chief Medical Advisor (USA). Dr. Goldstein supports NTI164, Neurotech’s consistent,

“We now have the clinical data, regulatory momentum, and leadership to deliver NTI164 to patients globally,” Chairman Mark Davies said. FY25 was a turning point,” Davies said. “With a strong clinical package, regulatory recognition, and an experienced team, Neurotech is

Our Principal Investigator, Professor Russell Dale, who leads our Phase I/II PANDAS/PANS clinical trial, has had a new paper published in nature (Molecular Psychiatry). This recognition underscores the calibre of clinical leadership guiding NTI164’s development and builds